S. Yin

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

R. Stocco, A. Roulston, Jordan T. F. Young, 2021, Molecular Cancer Therapeutics.